Repurposing current therapeutic regimens against SARS-CoV-2 (Review)
- Authors:
- Sofia K. Konstantinidou
- Ioannis P. Papanastasiou
-
Affiliations: Oncology Unit, The Third Department of Medicine, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece, Division of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 15784 Athens, Greece - Published online on: June 18, 2020 https://doi.org/10.3892/etm.2020.8905
- Pages: 1845-1855
This article is mentioned in:
Abstract
Anastassopoulou C, Russo L, Tsakris A and Siettos C: Data-based analysis, modelling and forecasting of the COVID-19 outbreak. PLoS One. 15(e0230405)2020.PubMed/NCBI View Article : Google Scholar | |
Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 5:536–544. 2020. View Article : Google Scholar | |
Almeida JD and Tyrrell DAJ: The morphology of three previously uncharacterized human respiratory viruses that grow in organ culture. J Gen Virol. 1:175–178. 1967.PubMed/NCBI View Article : Google Scholar | |
Docea AO, Tsatsakis A, Albulescu D, Cristea O, Zlatian O, Vinceti M, Moschos SA, Tsoukalas D, Goumenou M, Drakoulis N, et al: A new threat from an old enemy: Re emergence of coronavirus (Review). Int J Mol Med. 45:1631–1643. 2020.PubMed/NCBI View Article : Google Scholar | |
Ye ZW, Yuan S, Yuen KS, Fung SY, Chan CP and Jin DY: Zoonotic origins of human coronaviruses. Int J Biol Sci. 16:1686–1697. 2020.PubMed/NCBI View Article : Google Scholar | |
Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, Tong S, Urbani C, Comer JA, Lim W, et al: SARS Working Group: A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 348:1953–1966. 2003.PubMed/NCBI View Article : Google Scholar | |
Fehr AR, Channappanavar R and Perlman S: Middle East respiratory syndrome (MERS): Emergence of a pathogenic human Coronavirus. Annu Rev Med. 68:387–399. 2017.PubMed/NCBI View Article : Google Scholar | |
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, et al: Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet. 395:565–574. 2020.PubMed/NCBI View Article : Google Scholar | |
Gates B: Responding to Covid-19 - A Once-in-a-Century Pandemic? N Engl J Med. 382:1677–1679. 2020.PubMed/NCBI View Article : Google Scholar | |
Gates B: Innovation for Pandemics. N Engl J Med. 378:2057–2060. 2018.PubMed/NCBI View Article : Google Scholar | |
Wu G, Zhao T, Kang D, Zhang J, Song Y, Namasivayam V, Kongsted J, Pannecouque C, De Clercq E, Poongavanam V, et al: Overview of recent strategic advances in medicinal chemistry. J Med Chem. 62:9375–9414. 2019.PubMed/NCBI View Article : Google Scholar | |
Touret F and de Lamballerie X: Of chloroquine and COVID-19. Antiviral Res. 177(104762)2020.PubMed/NCBI View Article : Google Scholar | |
Cortegiani A, Ingoglia G, Ippolito M, Giarratano A and Einav S: A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 57:279–283. 2020.PubMed/NCBI View Article : Google Scholar | |
Colson P, Rolain JM, Lagier JC, Brouqui P and Raoult D: Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 55(105932)2020.PubMed/NCBI View Article : Google Scholar | |
Ben-Zvi I, Kivity S, Langevitz P and Shoenfeld Y: Hydroxychloroquine: From malaria to autoimmunity. Clin Rev Allergy Immunol. 42:145–153. 2012.PubMed/NCBI View Article : Google Scholar | |
Witiak DT, Grattan DA, Heaslip RJ and Rahwan RG: Synthesis and preliminary pharmacological evaluation of asymmetric chloroquine analogues. J Med Chem. 24:712–717. 1981.PubMed/NCBI View Article : Google Scholar | |
Chloroquine- an overview | ScienceDirect Topics. Sci Direct. | |
Circu M, Cardelli J, Barr MP, O'Byrne K, Mills G and El-Osta H: Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells. PLoS One. 12(e0184922)2017.PubMed/NCBI View Article : Google Scholar | |
Schrezenmeier E and Dörner T: Mechanisms of action of hydroxychloroquine and chloroquine: Implications for rheumatology. Nat Rev Rheumatol. 16:155–166. 2020.PubMed/NCBI View Article : Google Scholar | |
van den Borne BEEM, Dijkmans BAC, de Rooij HH, le Cessie S and Verweij CL: Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-α, interleukin 6, and interferon-γ production by peripheral blood mononuclear cells. J Rheumatol. 24:55–60. 1997.PubMed/NCBI | |
Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, O'Meara MJ, Rezelj VV, Guo JZ, Swaney DL, et al: A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. Apr 30. 2020.(Epub ahead of print).PubMed/NCBI View Article : Google Scholar | |
Encinar JA and Menendez JA: Potential drugs targeting early innate immune evasion of SARS-coronavirus 2 via 2'-O-methylation of viral RNA. Viruses. 12(E525)2020.PubMed/NCBI View Article : Google Scholar | |
Keyaerts E, Vijgen L, Maes P, Neyts J and Van-Ranst M: In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 323:264–268. 2004.PubMed/NCBI View Article : Google Scholar | |
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W and Xiao G: Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30:269–271. 2020.PubMed/NCBI View Article : Google Scholar | |
Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z, Zhong W and Wang M: Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 6(16)2020.PubMed/NCBI View Article : Google Scholar | |
Hache Guillaume RJMGP, DJBPRDHS: Hydroxychloroquine-Azithromycin and COVID-19 - IHU, 2020. | |
Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, Weinberg P, Kirkwood J, Muse A, DeHovitz J, et al: Association of treatment with hydroxychloroquine or azithromycin with in-Hospital Mortality in patients with COVID-19 in New York State. JAMA. May 11. 2020.PubMed/NCBI View Article : Google Scholar : (Epub ahead of print). View Article : Google Scholar | |
Doudier B and Courjon J: Hydroxychloroquine and azithromycin as a treatment of COVID-19. 2020.PubMed/NCBI View Article : Google Scholar | |
Gao J, Tian Z and Yang X: Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 14:72–73. 2020.PubMed/NCBI View Article : Google Scholar | |
Zhao M: Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies. Int J Antimicrob Agents. 55(105982)2020.PubMed/NCBI View Article : Google Scholar | |
Efficacy and safety of hydroxychloroquine for treatment of COVID-19. uriClinicalTrials.govsimpleClinicalTrials.gov. | |
Comparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus disease (COVID-19). uriClinicalTrials.govsimpleClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04307693. Accessed March 13, 2020. | |
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, et al: In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. Mar 9. 2020.PubMed/NCBI View Article : Google Scholar : (Epub ahead of print). View Article : Google Scholar | |
The PATCH Trial (prevention and treatment of COVID-19 with hydroxychloroquine). uriClinicalTrials.govsimpleClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04329923. Accessed April 1, 2020. | |
Karalis V, Ismailos G and Karatza E: Chloroquine dosage regimens in patients with COVID-19: safety risks and optimization using simulations. Saf Sci. 129(104842)2020.PubMed/NCBI View Article : Google Scholar | |
Lane JC, Weaver J, Kostka K, Duarte-Salles T, Abrahao MT, Alghoul H, Alser O, Alshammari TM, Biedermann P, Burn E, et al: Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study. medRxiv. May 31. 2020. View Article : Google Scholar : (Epub ahead of print). View Article : Google Scholar | |
Al-Bari MA: Chloroquine analogues in drug discovery: New directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother. 70:1608–1621. 2015.PubMed/NCBI View Article : Google Scholar | |
Mehra MR, Desai SS, Ruschitzka F and Patel AN: Articles Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: A multinational registry analysis. Lancet. 6736:1–10. 2020. View Article : Google Scholar | |
Karalis V, Ismailos G and Karatza E: Chloroquine dosage regimens in patients with COVID-19: Safety risks and optimization using simulations. Saf Sci. 129(104842)2020.PubMed/NCBI View Article : Google Scholar | |
Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, Brown TS, Der Nigoghossian C, Zidar DA, Haythe J, et al: Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 75:2352–2371. 2020.PubMed/NCBI View Article : Google Scholar | |
Deftereos SG, Siasos G, Giannopoulos G, Vrachatis DA, Angelidis C, Giotaki SG, Gargalianos P, Giamarellou H, Gogos C, Daikos G, et al: The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design. Hellenic J Cardiol. Apr 3. 2020.PubMed/NCBI View Article : Google Scholar : (Epub ahead of print). View Article : Google Scholar | |
Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA). uriClinicalTrials.govsimpleClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04322682. Accessed March 26, 2020. | |
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT and Veesler D: Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 181(281-292.e6)2020.PubMed/NCBI View Article : Google Scholar | |
Morse JS, Lalonde T, Xu S and Liu WR: Learning from the past: Possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. ChemBioChem. 21:730–738. 2020.PubMed/NCBI View Article : Google Scholar | |
Li F: Receptor recognition and cross-species infections of SARS coronavirus. Antiviral Res. 100:246–254. 2013.PubMed/NCBI View Article : Google Scholar | |
Ocaranza MP, Michea L, Chiong M, Lagos CF, Lavandero S and Jalil JE: Recent insights and therapeutic perspectives of angiotensin-(1-9) in the cardiovascular system. Clin Sci (Lond). 127:549–557. 2014.PubMed/NCBI View Article : Google Scholar | |
Li SR, Tang ZJ, Li ZH and Liu X: Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV. Eur J Clin Microbiol Infect Dis. 39:1021–1026. 2020.PubMed/NCBI View Article : Google Scholar | |
Yan T, Xiao R and Lin G: Angiotensin-converting enzyme 2 in severe acute respiratory syndrome coronavirus and SARS-CoV-2: A double-edged sword? FASEB J. 34:6017–6026. 2020.PubMed/NCBI View Article : Google Scholar | |
Imai Y, Kuba K and Penninger JM: The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. Exp Physiol. 93:543–548. 2008.PubMed/NCBI View Article : Google Scholar | |
Rothlin RP, Vetulli HM, Duarte M and Pelorosso FG: Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19. Drug Dev Res. May 1. 2020.PubMed/NCBI View Article : Google Scholar : (Epub ahead of print). View Article : Google Scholar | |
Zhang H, Penninger JM, Li Y, Zhong N and Slutsky AS: Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target. Intensive Care Med. 46:586–590. 2020.PubMed/NCBI View Article : Google Scholar | |
Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M and Mayhew S: The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 19:305–306. 2020.PubMed/NCBI View Article : Google Scholar | |
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, et al: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 181(271-280.e8)2020.PubMed/NCBI View Article : Google Scholar | |
Iwata-Yoshikawa N, Okamura T, Shimizu Y, Hasegawa H, Takeda M and Nagata N: TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection. J Virol. 93(93)2019.PubMed/NCBI View Article : Google Scholar | |
Verdecchia P, Cavallini C, Spanevello A and Angeli F: The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med. 76:14–20. 2020.PubMed/NCBI View Article : Google Scholar | |
Saavedra JM: Angiotensin receptor blockers and COVID-19. Pharmacol Res. 156(104832)2020.PubMed/NCBI View Article : Google Scholar | |
Fang L, Karakiulakis G and Roth M: Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 8(e21)2020.PubMed/NCBI View Article : Google Scholar | |
Diaz JH: Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19 Running Title: Angiotensin Receptor and COVID-19. J Travel Med. 27(taaa041)2020.PubMed/NCBI View Article : Google Scholar | |
Gurwitz D: Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 1(4)2020.PubMed/NCBI View Article : Google Scholar | |
Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, Liu YM, Zhao YC, Huang X, Lin L, et al: Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 126:1671–1681. 2020.PubMed/NCBI View Article : Google Scholar | |
Castiglione V, Chiriacò M, Emdin M, Taddei S and Vergaro G: Statin therapy in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother. Apr 29. 2020.PubMed/NCBI View Article : Google Scholar : (Epub ahead of print). View Article : Google Scholar | |
Pertzov B, Eliakim-Raz N, Atamna H, Trestioreanu AZ, Yahav D and Leibovici L: Hydroxymethylglutaryl-CoA reductase inhibitors (statins) for the treatment of sepsis in adults - A systematic review and meta-analysis. Clin Microbiol Infect. 25:280–289. 2019.PubMed/NCBI View Article : Google Scholar | |
Fedson DS, Opal SM and Rordam OM: Hiding in plain sight: An approach to treating patients with severe covid-19 infection. mBio. 11(e00398-20)2020.PubMed/NCBI View Article : Google Scholar | |
Journal EH, Pharmacotherapy C, East M: OUP accepted manuscript. Eur Hear J Cardiovasc Pharmacother 2020. | |
Li G and De Clercq E: Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 19:149–150. 2020.PubMed/NCBI View Article : Google Scholar | |
Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, et al: Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 531:381–385. 2016.PubMed/NCBI View Article : Google Scholar | |
Cho A, Saunders OL, Butler T, Zhang L, Xu J, Vela JE, Feng JY, Ray AS and Kim CU: Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. Bioorg Med Chem Lett. 22:2705–2707. 2012.PubMed/NCBI View Article : Google Scholar | |
Stambaský J, Hocek M and Kocovský P: C-nucleosides: Synthetic strategies and biological applications. Chem Rev. 109:6729–6764. 2009.PubMed/NCBI View Article : Google Scholar | |
Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S and Hall MD: Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent Sci. 6:672–683. 2020.PubMed/NCBI View Article : Google Scholar | |
Gilead announces results from phase 3 trial of investigational antiviral remdesivir in patients with severe COVID-19. Gilead Sciences, Inc., 2020. | |
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, et al: Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 395:1569–1578. 2020.PubMed/NCBI View Article : Google Scholar | |
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, et al: Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 382:2327–2336. 2020.PubMed/NCBI View Article : Google Scholar | |
Adaptive COVID-19 Treatment Trial (ACTT). uriClinicalTrials.govsimpleClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04280705. Accessed February 21, 2020. | |
Study to evaluate the safety and antiviral activity of remdesivir (GS-5734TM) in participants with moderate coronavirus disease (COVID-19) compared to standard of care treatment. uriClinicalTrials.govsimpleClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04292730. Accessed March 3, 2020. | |
Study to Evaluate the safety and antiviral activity of remdesivir (GS-5734TM) in participants with severe coronavirus disease (COVID-19). uriClinicalTrials.govsimpleClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04292899. Accessed March 3, 2020. | |
Furuta Y, Komeno T and Nakamura T: Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad, Ser B, Phys Biol Sci. 93:449–463. 2017.PubMed/NCBI View Article : Google Scholar | |
Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, Nomura N, Egawa H and Shiraki K: Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother. 49:981–986. 2005.PubMed/NCBI View Article : Google Scholar | |
Smee DF, Hurst BL, Egawa H, Takahashi K, Kadota T and Furuta Y: Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells. J Antimicrob Chemother. 64:741–746. 2009.PubMed/NCBI View Article : Google Scholar | |
Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, Liao X, Gu Y, Cai Q, Yang Y, et al: Experimental treatment with favipiravir for COVID-19: An open-label control study. Engineering (Beijing). Mar 18. 2020.PubMed/NCBI View Article : Google Scholar : (Epub ahead of print). View Article : Google Scholar | |
Chen C, Huang J, Cheng Z, Wu J, Chen S, Yongxi Zhang Y, Chen B, Lu M, Luo Y, Zhang J, et al: Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv. April 15. 2020.(Epub ahead or ptint). View Article : Google Scholar | |
Clinical study to evaluate the performance and safety of favipiravir in COVID-19. uriClinicalTrials.govsimpleClinicalTrials.gov. | |
Efficacy and safety of favipiravir in management of COVID-19. uriClinicalTrials.govsimpleClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04349241. Accessed April 16, 2020. | |
Clinical trial of favipiravir tablets combine with chloroquine phosphate in the treatment of novel coronavirus pneumonia. uriClinicalTrials.govsimpleClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04319900. Accessed March 24, 2020. | |
Favipiravir combined with tocilizumab in the treatment of corona virus disease 2019. uriClinicalTrials.govsimpleClinicalTrials.gov. | |
Cinatl J Jr, Michaelis M, Hoever G, Preiser W and Doerr HW: Development of antiviral therapy for severe acute respiratory syndrome. Antiviral Res. 66:81–97. 2005.PubMed/NCBI View Article : Google Scholar | |
Leyssen P, Balzarini J, De Clercq E and Neyts J: The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol. 79:1943–1947. 2005.PubMed/NCBI View Article : Google Scholar | |
Ning Q, Brown D, Parodo J, Cattral M, Gorczynski R, Cole E, Fung L, Ding JW, Liu MF, Rotstein O, et al: Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol. 160:3487–3493. 1998.PubMed/NCBI | |
Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, Montgomery SA, Hogg A, Babusis D, Clarke MO, et al: Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 11(222)2020.PubMed/NCBI View Article : Google Scholar | |
Agbowuro AA, Huston WM, Gamble AB and Tyndall JD: Proteases and protease inhibitors in infectious diseases. Med Res Rev. 38:1295–1331. 2018.PubMed/NCBI View Article : Google Scholar | |
Delang L and Neyts J: Medical treatment options for COVID-19. Eur Heart J Acute Cardiovasc Care. 9:209–214. 2020.PubMed/NCBI View Article : Google Scholar | |
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, et al: A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 382:1787–1799. 2020. View Article : Google Scholar | |
The efficacy of lopinavir plus ritonavir and arbidol against novel coronavirus infection. uriClinicalTrials.govsimpleClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04252885. Accessed February 5, 2020. | |
Lopinavir/ritonavir ribavirin and IFN-beta combination for nCoV treatment. uriClinicalTrials.govsimpleClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04276688. Accessed February 19, 2020. | |
Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, Ng YY, Lo J, Chan J, Tam AR, et al: Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: An open-label, randomised, phase 2 trial. Lancet. 395:1695–1704. 2020. View Article : Google Scholar | |
Andersen PI, Krpina K, Ianevski A, Shtaida N, Jo E, Yang J, Koit S, Tenson T, Hukkanen V, Anthonsen MW, et al: Novel antiviral activities of obatoclax, emetine, niclosamide, brequinar, and homoharringtonine. Viruses. 11:1–15. 2019.PubMed/NCBI View Article : Google Scholar | |
Choy KT, Wong AY, Kaewpreedee P, Sia SF, Chen D, Hui KP, Chu DK, Chan MC, Cheung PP, Huang X, et al: Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 178(104786)2020.PubMed/NCBI View Article : Google Scholar | |
Zhang C, Wu Z, Li JW, Zhao HW and Wang GQ: The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 11:1–6. 2020.PubMed/NCBI View Article : Google Scholar | |
Hennon TR, Penque MD, Abdul-Aziz R, Alibrahim OS, McGreevy MB, Prout AJ, Schaefer BA, Ambrusko SJ, Pastore JV, Turkovich SJ, et al: COVID-19 associated multisystem inflammatory syndrome in children (MIS-C) guidelines; a Western New York approach. Prog Pediatr Cardiol. 21(101232)2020. View Article : Google Scholar | |
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 395:497–506. 2020.PubMed/NCBI View Article : Google Scholar | |
Vijayvargiya P, Garrigos ZE, Almeida NE, Gurram PR, Stevens RW and Razonable RR: In reply-The ‘Perfect Cytokine Storm’ of COVID-19. Mayo Clin Proc. May 29. 2020. View Article : Google Scholar : (Epub ahead of print). View Article : Google Scholar | |
CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI). uriClinicalTrials.govsimpleClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04331808. Accessed April 2, 2020. | |
Fu B, Xu X and Wei H: Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med. 18(164)2020.PubMed/NCBI View Article : Google Scholar | |
Zhang Q, Wang Y, Qi C, Shen L and Li J: Response to ‘Comments on Zhang et al: Clinical trial analysis of 2019-nCoV therapy registered in China’. J Med Virol. 92(713)2020.PubMed/NCBI View Article : Google Scholar | |
Tocilizumab treatment in patients with COVID-19. uriClinicalTrials.govsimpleClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04363853. Accessed April 27, 2020. | |
Tocilizumab in the treatment of coronavirus induced disease (COVID-19). uriClinicalTrials.govsimpleClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04335071. Accessed April 6, 2020. | |
A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia. uriClinicalTrials.govsimpleClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04320615. Accessed March 25, 2020. | |
Genentech's arthritis drug tocilizumab shows promise in Covid-19 trial. ClinicalTrials Arena, 2020. https://www.clinicaltrialsarena.com/uncategorized/genentechs-arthritis-drug-tocilizumab-shows-promise-in-covid-19-trial/. Accessed April 29, 2020. | |
Andreakos E and Tsiodras S: COVID-19: Lambda interferon against viral load and hyperinflammation. EMBO Mol Med. 12(e12465)2020.PubMed/NCBI View Article : Google Scholar | |
Davidson S, McCabe TM, Crotta S, Gad HH, Hessel EM, Beinke S, Hartmann R and Wack A: IFNλ is a potent anti-influenza therapeutic without the inflammatory side effects of IFNα treatment. EMBO Mol Med. 8:1099–1112. 2016.PubMed/NCBI View Article : Google Scholar | |
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS and Manson JJ: HLH Across Speciality Collaboration, UK. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet. 395:1033–1034. 2020.PubMed/NCBI View Article : Google Scholar | |
Prokunina-Olsson L, Alphonse N, Dickenson RE, Durbin JE, Glenn JS, Hartmann R, Kotenko SV, Lazear HM, O'Brien TR, Odendall C, et al: COVID-19 and emerging viral infections: The case for interferon lambda. J Exp Med. 217:5–8. 2020.PubMed/NCBI View Article : Google Scholar | |
Bray M, Rayner C, Noël F, Jans D and Wagstaff K: Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses. Antiviral Res. 178(104805)2020.PubMed/NCBI View Article : Google Scholar | |
Caly L, Druce JD, Catton MG, Jans DA and Wagstaff KM: The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 178(104787)2020.PubMed/NCBI View Article : Google Scholar | |
González Canga A, Sahagún Prieto AM, Diez Liébana MJ, Fernández Martínez N, Sierra Vega M and García Vieitez JJ: The pharmacokinetics and interactions of ivermectin in humans - a mini-review. AAPS J. 10:42–46. 2008.PubMed/NCBI View Article : Google Scholar | |
Buonfrate D, Salas-Coronas J, Muñoz J, Maruri BT, Rodari P, Castelli F, Zammarchi L, Bianchi L, Gobbi F, Cabezas-Fernández T, et al: Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): A multicentre, open-label, phase 3, randomised controlled superiority trial. Lancet Infect Dis. 19:1181–1190. 2019. View Article : Google Scholar | |
Kelleni MT: Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management. Pharmacol Res. 157(104874)2020.PubMed/NCBI View Article : Google Scholar | |
Padmanabhan S: Potential dual therapeutic approach against SARS-CoV-2/COVID-19 with nitazoxanide and hydroxychloroquine. Preprint. 2020.PubMed/NCBI View Article : Google Scholar | |
Ulloa L: The vagus nerve and the nicotinic anti-inflammatory pathway. Nat Rev Drug Discov. 4:673–684. 2005.PubMed/NCBI View Article : Google Scholar | |
Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, Dubnov-Raz G, Esposito S, Ganmaa D, Ginde AA, et al: Vitamin D supplementation to prevent acute respiratory tract infections: Systematic review and meta-analysis of individual participant data. BMJ. 356(i6583)2017.PubMed/NCBI View Article : Google Scholar | |
Helming L, Böse J, Ehrchen J, Schiebe S, Frahm T, Geffers R, Probst-Kepper M, Balling R and Lengeling A: 1α,25-Dihydroxyvitamin D3 is a potent suppressor of interferon γ-mediated macrophage activation. Blood. 106:4351–4358. 2005.PubMed/NCBI View Article : Google Scholar | |
Ilie PC, Stefanescu S and Smith L: The role of Vitamin D in the prevention of Coronavirus Disease 2019 infection and mortality. Aging Clin Exp Res. May 6. 2020.PubMed/NCBI View Article : Google Scholar : (Epub ahead of print). View Article : Google Scholar | |
Alexander OM: Evidence on spironolactone safety in COVID-19 reassuring. Medscape. April 29. 2020.(Epub ahead of print). | |
Gustavo Carlos Wambier GA: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen mediated. J Am Acad Dermatol. 21:1–9. 2020.PubMed/NCBI View Article : Google Scholar | |
Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, Liu S and Yang JK: Gender differences in patients with COVID-19: Focus on severity and mortality. Front Public Health. 8(152)2020.PubMed/NCBI View Article : Google Scholar | |
Spironolactone in Covid-19 Induced ARDS. uriClinicalTrials.govsimpleClinicalTrials.gov. https://www.smartpatients.com/trials/NCT04345887. Accessed April, 2020. | |
Kleinnijenhuis J, Quintin J, Preijers F, Benn CS, Joosten LA, Jacobs C, van Loenhout J, Xavier RJ, Aaby P, van der Meer JW, et al: Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity. J Innate Immun. 6:152–158. 2014.PubMed/NCBI View Article : Google Scholar | |
Gearoid R: Japan was expecting a coronavirus explosion. Where is it? The Japan Times. 2020. | |
Moorlag SJ, Arts RJ, van Crevel R and Netea MG: Non-specific effects of BCG vaccine on viral infections. Clin Microbiol Infect. 25:1473–1478. 2019.PubMed/NCBI View Article : Google Scholar | |
BCG Vaccination to Protect Healthcare Workers Against COVID-19. uriClinicalTrials.govsimpleClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04327206. Accessed March 31, 2020. | |
BCG vaccine for health care workers as defense against COVID-19. uriClinicalTrials.govsimpleClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04348370. Accessed April 16, 2020. | |
Saad M and Elsalamony R: Measles vaccines may provide partial protection against COVID-19. Int J Cancer Biomed Res. 5:14–19. 2020. View Article : Google Scholar | |
Fischer JC, Zänker K, van Griensven M, Schneider M, Kindgen-Milles D, Knoefel WT, Lichtenberg A, Tamaskovics B, Djiepmo-Njanang FJ, Budach W, et al: The role of passive immunization in the age of SARS-CoV-2: An update. Eur J Med Res. 25(16)2020.PubMed/NCBI View Article : Google Scholar | |
Keith P, Day M, Perkins L, Moyer L, Hewitt K and Wells A: A novel treatment approach to the novel coronavirus: An argument for the use of therapeutic plasma exchange for fulminant COVID-19. Crit Care. 24(128)2020. View Article : Google Scholar | |
Lennart H, Hassan A, Fausto B, Harold M and Hammarström QP: Development of passive immunity against SARS-CoV-1 2 for management of immunodeficient patients - a perspective. J Allergy Clin Immunol. May 12. 2020.(Epub ahead of print). View Article : Google Scholar | |
Honore PM, Mugisha A, Kugener L, Redant S, Attou R, Gallerani A and De Bels D: Therapeutic plasma exchange as a routine therapy in septic shock and as an experimental treatment for COVID-19: We are not sure. Crit Care. 24(226)2020.PubMed/NCBI View Article : Google Scholar | |
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial. uriClinicalTrials.govsimpleClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04330690. Accessed April 1, 2020. | |
Randomized embedded multifactorial adaptive platform trial for community- acquired pneumonia. uriClinicalTrials.govsimpleClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02735707. Accessed April 13, 2016. | |
Trial of treatments for COVID-19 in hospitalized adults. uriClinicalTrials.govsimpleClinicalTrials.gov. https://www.centerwatch.com/clinical-trials/listings/241173/corona-virus-infection-trial-treatments-covid-19-hospitalized/?&radius=50. Accessed June 2020. |